The US Food and Drug Administration (FDA) on Monday licensed using the Pfizer-BioNTech Covid-19 vaccine on youngsters aged 12 to fifteen years previous.
Acting FDA commissioner Janet Woodcock described the transfer as a “significant step in the fight against the Covid-19 pandemic.”
“Today’s action allows for a younger population to be protected from Covid-19, bringing us closer to returning to a sense of normalcy and to ending the pandemic,” Woodcock stated in a press release.
“Parents and guardians can rest assured that the agency undertook a rigorous and thorough review of all available data, as we have with all of our Covid-19 vaccine emergency use authorizations,” she added.
The FDA beforehand granted an emergency use authorization for the Pfizer-BioNTech vaccine to people aged 16 and older.
“Having a vaccine authorized for a younger population is a critical step in continuing to lessen the immense public health burden caused by the Covid-19 pandemic,” stated Peter Marks, director of the FDA’s Center for Biologics Evaluation and Research.
The FDA stated some 1.5 million Covid-19 circumstances in people aged 11 to 17 years previous have been reported to the Centers for Disease Control and Prevention between March 1, 2020 via April 30, 2021.
The course of the illness is usually milder in children however they’ll move it on to older, extra susceptible adults.